Table 1.
Cohort characteristics.
| Number of patients | 36 |
| Median age in years (IQR) | 69.7 (58.8–76.8) |
| Median follow-up for entire cohort in months (IQR) | 16.8 (9.3–38.7) |
| Gender | |
| Male | 30 (83%) |
| Female | 6 (17%) |
| Race | |
| Caucasian | 32 (88.8%) |
| Other | 4 (11.2%) |
| Urothelial cell carcinoma variant | |
| None | 14 (38.9%) |
| Small cell | 9 (25.0%) |
| Micropapillary | 5 (13.9%) |
| Other* | 5 (13.9%) |
| Not available | 3 (8.3%) |
| Prechemotherapy clinical stage | |
| cT2 | 22 (61.1%) |
| cT3 | 10 (27.7%) |
| cT4 | 2 (5.6%) |
| Not available | 2 (5.6%) |
| Prechemotherapy carcinoma in situ | |
| Present | 21 (58.3%) |
| Not present | 12 (33.3%) |
| Not available | 3 (8.3%) |
| Prechemotherapy clinical nodal status | |
| cN0 | 28 (77.8%) |
| cN+ | 6 (16.7%) |
| Not available | 3 (5.6%) |
| Chemotherapy regimen | |
| Gemcitabine and cisplatin | 20 (55.5%) |
| Etoposide and cisplatin | 7 (19.4%) |
| Paclitaxel, ifosfamide, and cisplatin | 3 (8.3%) |
| Methotrexate, vinblastine, doxorubicin, and cisplatin | 2 (5.6%) |
| Other | 3 (8.3%) |
| Not available | 1 (2.8%) |
| Postchemotherapy clinical stage | |
| cT0 | 21 (58.3%) |
| cTis | 3 (8.3%) |
| cT1 | 1 (2.7%) |
| cT2 | 6 (16.7%) |
| cT3 | 2 (5.6%) |
| cT4 | 1 (2.8%) |
| Not available | 2 (5.6%) |
| Postchemotherapy CIS | |
| Present | 5 (13.9%) |
| Not present | 26 (72.2%) |
| Not available | 5 (13.9%) |
| Postchemotherapy clinical nodal status | |
| cN0 | 31 (86.1%) |
| cN+ | 4 (11.1%) |
| Not available | 1 (2.8%) |
| Postchemotherapy median follow-up in months (IQR)∧ | |
| cT0 | 17.8 (12.8–34.3) |
| >cT0 | 16.8 (4.4–43.1) |
| Final pathologic stage | |
| pT0 | 18 (50.0%) |
| pTis | 6 (16.7%) |
| pT1 | 2 (5.6%) |
| pT2 | 3 (8.3%) |
| pT3 | 7 (19.4%) |
| Final pathology carcinoma in situ | |
| Present | 14 (38.9%) |
| Not present | 22 (61.1%) |
| Not available | 0 (0%) |
| Final pathologic nodal involvement | |
| pN0 | 27 (75.0%) |
| pN+ | 4 (11.1%) |
| Not available | 5 (13.9%) |
| Surgical margin (SM) | |
| SM− | 15 (41.7%) |
| SM+ | 3 (8.3%) |
| NA (pT0) | 18 (50.0%) |
*Other urothelial cell carcinoma variants include glandular (2) and plasmacytoid (2).
∧No difference in median follow-up by rank sum test, P = 0.67.